The time necessary for dissipation of radioactive labelled propranolol and its metabolites and the cardiac effects of this agent in the hearts of patients undergoing open-heart surgery were studied. Isoprenaline produced chronotropic and inotropic responses in atrial muscle in tissue bath studies which were normal 8 to I2 hours after withdrawing propranolol. After the administration of either 25 or 75 ,uCi of "4C-labelled propranolol, the myocardial tissue concentration declined to insignificant levels between 24 and 28 hours. We conclude that withdrawal ofpropranolol therapy 24 to 48 hours before cardiac surgery should be acceptable.
is unlikely that ischaemic heart disease would progress as the result of withdrawing the drug for this period of time. However, it may not be possible or necessary to withhold surgery for such a long period of time in patients receiving propranolol and in whom it is desired to stop the drug before surgery, since the drug has a serum half-life of only 3 to 6 hours .
In this study we present data on the residual in vitro pharmacological activity remaining in atria taken from cardiac patients who receive propranolol chronically, and information on the in vivo decay pattern of propranolol's chronotropic and inotropic activity in patients in whom serum and tissue levels were also deternined after administration of 14C-labelled propranolol. A study of concomitant pharmacological and drug metabolic residuals may assist in further defining the interval necessary for withdrawal of the drug before surgery.
Methods
Beta blockade was assessed in vitro in human atria and in vivo in patients before anaesthesia using noninvasive techniques. Serum levels and tissue residual concentrations of propranolol were determined following 14C-labelled propranolol administration using biochemical techniques (Coltart and Shand, I970) .
Investigation of the safe withdrawal period for propranolol in patients scheduled for open heart surgery 1229 propranolol patients).-Atrial and plasma samples were obtained during coronary artery bypass surgery in four patients who had not received propranolol (A), and in four in whom chronic propranolol treatment (80 mg six-hourly) had been discontinued for 24 to 72 hours preoperatively (B). The atrial tissue was examined for pharmacological activity by in vitro isoprenaline challenge (see below).
Group 2 (acute preoperative intravenous radioactive propranolol). In four patients undergoing mitral valve replacement a single dose of img uCi) Pharmacological studies In vitro Atrial tissue specimens from patients in Groups iA and iB were prepared as previously described (Coltart and Spilker, I972) , and an in vitro dosecontractility response curve to varying concentrations of isoprenaline was determined from patients (Group iB) who had been on chronic propranolol therapy and from control patients (Group iA). These studies were carried out in a muscle bath at 370 C by standard isometric techniques (Coltart and Spilker, I972) . In vivo In two patients from each of Groups 2, 3A, and 3B the degree of beta blockade was determined according to Cleaveland, Rangno, and Shand (1972) by estimating the dose of bolus injections of isoprenaline required to increase the resting heart rate by 25 beats/ min. Systolic time interval changes in response to isoprenaline were also measured, and the dose required to shorten the pre-ejection phase (PEP) by 50 ms was determined (Weissler, Harris, and Schoenfeld, I968) . These isoprenaline challenges were performed prior to and at 30-min intervals after administration of oral or intravenous propranolol.
Biochemical and radioactivity measurements
Plasma levels Plasma propranolol levels were measured by a modification (M. Kraml, in preparation) of the fluorometric procedure of Shand, Nuckolls, and Oates (1970) . The sensitivity of the method was io ng/ml (2 ml of plasma was assayed). In order to improve the sensitivity of the plasma propranolol measurement in patients treated intravenously with I mg 14C-labelled propranolol the radioactivity content of the final HC1 solution (i.e., the HC1 extract of the heptane-isoamyl alcohol extract of the alkalinized serum) was also measured. This HC1 solution, which is normally used for the measurement of fluorescence due to propranolol, contains only propranolol and possibly its basic metabolite(s) (Hayes and Cooper, I97I) . The only known basic metabolite of propranolol is Ndesisopropylpropranolol (Walle and Gaffney, 1972) . Although it was not measured specifically, it is unlikely that this extract contains any 4-hydroxypropranolol. This metabolite is unstable in the extraction procedure (Hayes and Cooper, I971) ; it is formed after oral but not after intravenous propranolol (Cleaveland and Shand, I972; Shand and Rangno, I972) . When 0.2 ml of the HC1 extract was counted in Bray's solution (Bray, I960 ) the sensitivity of propranolol determination in subjects treated intravenously with i mg of the drug was increased to i ng/ml. When the drug was given orally, the specific activity of the administered dose was too low, and this procedure did not enhance the sensitivity of propranolol measurement.
Total plasma radioactivity levels were measured by liquid scintillation spectrometry after digestion of 0.2 ml aliquots with 2 ml Soluene (R) (a tissue solubilizer obtained from Packard Instrument Co., Downers Grove, Illinois) and addition of I5 ml scintillation fluid comprising 5 g Omnifluor(R) (New England Nuclear Corp., Boston, Massachusetts) per litre of toluene.
Tissue levels Tissue levels of unchanged 14C-labelled propranolol and its basic metabolite(s) were measured according to Hayes and Cooper (I971) . Samples (approximately I g) were homogenized in I0% sodium carbonate solution. The homogenate was mechanically shaken for 20 minutes with I0 ml toluene. After centrifugation at 2000 rev/min for I0 minutes 5 ml of the toluene layer was added to I0 ml toluene phosphor solution of 3/2 normal strength, and counted. Since this procedure may (Hayes and Cooper, 1971) or may not (D. M. Foulkes, I973, personal communication) extract small amounts of 4-hydroxypropranolol, the relevant data in Tables 2 and 4 (which have been expressed as ng unchanged propranolol/g tissue) represent maximum values for unchanged tissue propranolol levels.
Tissue total radioactivity levels were measured after digestion of duplicate 50-I00 mg aliquots in Soluene. After addition of scintillation fluid, samples were placed in the dark for 24 hours to minimize chemiluminescence and counted until successive counts were stable.
The limits of sensitivity of radioactivity measurements in serum and tissue are presented in Table i .
Results
In patients who had received propranolol chronically preoperatively (Group i) the fluorescence assay for propranolol failed to detect differences in fluorescence of plasma or atria between control patients and those in whom the drug had been discontinued 24 to 72 hours before surgery (B). These findings indicate that less than I0 ng/ml was present in the plasma. The isoprenaline dose-contractile response curve obtained in atria from patients 24 to 72 hours after discontinuation of propranolol was similar to that of control atria ( * Limits derived from the following sensitivities: 50 dpm/ml plasma for both total radioactivity and 14C propranolol, 400 dpm total radioactivity/g tissue, and 20 dpm 14C propranolol/g tissue. Differences in sensitivity for estimations from plasma and tissue are due to differences in sample size and extent of quenching.
chemically measurable propranolol nor evidence of pharmacological activity of either propranolol or possible active metabolites. Plasma radioactivity and propranolol levels of Group 2 patients who had received I mg of 14C-labelled propranolol intravenously are shown in Fig. 2 . Unchanged propranolol levels were too low to be detected by fluorescence (sensitivity IO ng/ml), but were above the level of sensitivity for radioactivity measurements (sensitivity i ng/ml). The serum half-life varied between I.5 and 5 hours. Table 3 shows the plasma radioactivity levels after Mizgala and Counsell, I974), and two reports (Jones et al., 1974; Levenson et al., 1974) suggest that cardiac surgery without discontinuing propranolol may be the treatment of choice. In our studies we have approached the problem by making associated pharmacological and biochemical measurements in cardiac patients. The choice to measure residual beta blockade in isolated atrial tissue or in intact man is reasonable, since the other actions of this drug or its metabolites occur only with higher doses, e.g. -quinidine-like activityor are associated with shorter half-life metabolitese.g., 4-hydroxypropranolol (Paterson et al., I970; Fitzgerald and O'Donnell, I97I) -and each of these would be less important in the 24-48-hour period after discontinuance of the drug when levels are low. Initial studies began with simple chemical fluorescent measurements for propranolol in serum or atria, in patients who had been receiving the drug chronically, and we included tests on the antagonism of isoprenaline in isolated organ baths. We failed to see any difference between control and propranolol patients, and these findings are consistent with reports by Faulkner et al. (I973) . This latter report was published after our studies were completed.
Next, we administered single doses of 14C-labelled propranolol intravenously or orally and then increased the dose of radioactivity to increase measurement sensitivity. Because we emphasized tissue radioactivity determinations, the number of studies which could be undertaken was limited, and the time of measurements was varied to screen for possible effects. We demonstrated levels of radioactive metabolites in human tissue, and this was expected from previous animal studies (Hayes and Cooper, I97I; Masuoka and Hansson, I967), which measured tissue levels, and from a clinical study (Paterson et al., I970) which measured serum levels of propranolol and radioactive metabolites. Little or no unchanged propranolol was detected even when 75 [±Ci of propranolol was administered, and then myocardial levels were below the levels which evidently could have affected chronotropic or inotropic responses to isoprenaline. The radioactive data from this clinical study are of necessity from administration of single doses, but they do support the observation that the principal drug effects (beta blockade) and tissue residues of pharmacological importance have virtually disappeared by 24 to 48 hours. Neither we nor others (Faulkner et al., 1973) could find evidence for dissociation of the effect of propranolol given chronically on the chronotropic and inotropic responses to isoprenaline as reported by Robinson, Rich, and Weissler (I973). Levenson et al. (I974) reported that while the haemodynamic effects of repeat-dose propranolol given to normal volunteers were dissipated by 72 hours after the last dose, in the immediate period after withdrawal of propranolol, haemodynamic effects persisted when blood levels had dropped. However, this study did not determine the complete dose-effect curve for the blood level-haemodynamic effect relationship and did not study the kinetics of both the pharmacological and biochemical measurements. Our conclusions are consistent with the recommendation made by Faulkner et al. (I973) from the results of their combined animal and human studies, though these studies did not include 14C-labelled propranolol administration nor human tissue level measurement.
This study was principally designed to determine the period necessary for dissipation of propranolol itself and its beta blockade in order to recommend a safe period for withdrawal. However, we would note that many (Slome, 1973; Mizgala and Counsell, I974) , including ourselves (Alderman et al., I974) , have reported that abrupt withdrawal of propranolol in some patients with severe coronary artery disease or unstable angina pectoris can cause rebound angina and even myocardial infarction. This complication appears to be related to diminished drug effects leaving the myocardium unprotected against stress, rather than from residual drug and continued pharmacological effects of propranolol. The recommendation for safe withdrawal should direct the physician to observe the patient closely for rebound and to be prepared to reinstitute drug therapy if deemed advisable. Under emergency situations in patients receiving propranolol it may be undesirable to withdraw the drug. Moran et al. (I973) and Jones et al. (I974) suggest that appropriately selected patients receiving propranolol throughout cardiac surgery may be at no greater risk than patients who had not received the drug. After completion of this study we retrospectively compared two consecutive series of ioo patients, each of whom had undergone elective vein bypass cardiac surgery for angina pectoris at Stanford University. In patients who had not received propranolol in the medical management of their symptoms before operation the average mortality was 5 per cent. In the series in which propranolol had been discontinued I to I0 days before surgery the mortality was 3 per cent. While this survey could not be considered definitive, the results are consistent with the Vanderbilt experience noted by FauLkner et al. (1973) and tend to refute the report by Viljoen et al. (I972) . A large, controlled series in which propranolol was or was not withdrawn before surgery, using a random selection process, could clarify the issues but would be difficult to undertake.
In conclusion, since propranolol is used for symptomatic relief in patients with angina pectoris rather than for a direct effect on underlying disease processes, it would seem logical to discontinue a drug with known negative inotropic effects before undertaking elective cardiac surgery. However, withdrawal may result in rebound angina and possibly myocardial infarction in some patients. The decline of the blockade of isoprenaline's chronotropic and inotropic activity, together with the measurement of unchanged 14C-labelled propranolol, indicates that 24 to 48 hours is a conservative estimate for a satisfactory withdrawal. This period of time would often conveniently coincide with the preoperative admission time of the patient, when the drug can safely be withdrawn or dosage reduced while the patient is 
